Press Releases

View Archive: 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003

11.17.06
FibroGen Reports Results of a Phase 1b Study of FG-3019, Therapeutic Antibody Against CTGF, in Diabetic Patients with Microalbuminuria

11.17.06
FibroGen Reports that FG-4539, HIF-PH Inhibitor, is Renoprotective and Improves Renal Function in Preclinical Models of Acute Kidney Injury

9.27.06
FibroGen and Shorenstein Properties Execute Build-to-Suit Construction and Long-term Lease for Mission Bay Property

9.13.06
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing

8.22.06
FibroGen Awarded Grant from National Heart, Lung, and Blood Institute to Develop HIF-PH Inhibitors to Treat Sickle Cell Disease

6.22.06
FibroGen Announces Investigational Anti-CTGF Therapeutic, FG-3019, Reduces Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

6.12.06
FibroGen Reports Combinations of FG-3019 plus ACEi and FG-3019 Plus ARB Prevented and Reversed Arterial Stiffness Significantly Better than ACEi or ARB Alone in Preclinical Models of Diabetes

4.28.06
FibroGen Licenses Oral HIF-PH Inhibitors, Including FG-2216 and FG-4592, to Astellas for the Treatment of Anemia in Europe and Other Regions

4.17.06
FibroGen Reports FG-4539, HIF-PH Inhibitor, Is Neuroprotective and Significantly Reduces Brain Tissue Damage in Preclinical Model of Ischemic Stroke